REPLIGEN CORP
RGENRepligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How RGEN's past catalysts played out
No drugs found in this phase.
Frequently asked questions
When is REPLIGEN CORP's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for REPLIGEN CORP (RGEN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RGEN biotech catalysts?→
Add RGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow REPLIGEN CORP's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.